The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 07, 2023

Filed:

Sep. 26, 2018
Applicant:

Osaka University, Suita, JP;

Inventors:

Akira Kikuchi, Suita, JP;

Katsumi Fumoto, Suita, JP;

Hirokazu Kimura, Suita, JP;

Assignee:

OSAKA UNIVERSITY, Suita, JP;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/18 (2006.01); A61P 35/00 (2006.01); G01N 33/543 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61P 35/00 (2018.01); G01N 33/543 (2013.01); G01N 33/57423 (2013.01); G01N 33/57438 (2013.01); A61K 39/00 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01);
Abstract

The purpose of the present invention is to provide an anti-CKAP4 monoclonal antibody that inhibits the binding of DKK1 and CKAP4 and exhibits an exceptional antitumor effect. Provided is an anti-CKAP4 monoclonal antibody that recognizes at least part of the 451-455 region, at least part of the 481-485 region, at least part of the 502-510 region, at least part of the 503-524 region and at least part of the 585-590 region, or at least part of the 585-592 region of the amino acid sequence (amino acid sequence of CKAP4) represented by SEQ ID NO:1 as an epitope, the anti-CKAP4 monoclonal antibody effectively inhibiting the binding of DKK1 and CKAP4, the activation of AKT of S2-CP8 cells, and the proliferative ability of S2-CP8 cells or the migratory ability of S2-CP8 cells, and exhibiting an exceptional antitumor effect. The ability to develop ELISA methods in which these anti-CKAP4 monoclonal antibodies are used furthermore makes it possible, for example, to measure the serum CKAP4 in pancreatic cancer patients, and therefore also contributes to the development of companion diagnostic agents.


Find Patent Forward Citations

Loading…